The global rare gastrointestinal diseases treatment market garnered a market value of US$ 1,314.8 million in 2022. The market is set to reach US$ 1,353.2 million in 2023 and is expected to register a CAGR of 3.7% from 2023 to 2033. Following this moderate growth rate, the worldwide adoption of gastrointestinal rare disease treatment could accumulate a market value of US$ 1,940.6 million by 2033.
The growth of the rare gastrointestinal diseases treatment market can be attributed to increasing awareness of gastrointestinal diseases and the development of various medications.
A rare gastrointestinal disease occurs uncommonly in the overall population. According to the International Rare Diseases Research Consortium (IRDiRC), it is a rare disease that affects less than 1 in 2,000 citizens. Gastrointestinal diseases affect fewer than 200,000 patients in the United States. Yet for the combined population of 800 million, this could range from a few hundred to as many as 400,000 individuals for any rare disease. In addition, government initiatives, funding, and collaboration in rare gastrointestinal disease projects are enhancing the treatment available for the market.
| Report Attributes or Data Points | Details |
|---|---|
| Global Rare Gastrointestinal Diseases Treatment Market Valuation in 2022 | US$ 1,314.8 million |
| Estimated Global Market Share in 2023 | US$ 1,353.2 million |
| Forecasted Global Market Size by 2033 | US$ 1,940.6 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 3.7% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 2.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In terms of value, the global demand for gastrointestinal rare disease treatment was a mere US$ 1,139.9 million in 2018. According to a recent report from FMI, during the historical period between 2018 and 2022, sales witnessed significant growth, registering a year-on-year growth rate of 2.9%.
Gastrointestinal rare disease treatment is available to overcome this life-threatening gastrointestinal rare disease that can help to reduce the impact on the worldwide diseased population. New therapies developed and approved by the specific regulatory authority can improve the quality and quantity of life.
Global cooperation and collaboration amongst scientists, researchers, companies, and government authorities create the opportunity to make new therapies for rare disease treatments.
Increasing awareness regarding treatments, along with the development of different methods of medicine, is accelerating the demand for the same. Improving healthcare systems, technology to detect gastrointestinal diseases, and immediate relief positively influences the demand for the gastrointestinal treatment market.
Rising Prevalence of Gastrointestinal Diseases Increasing Dependency on Treatment
Collectively, around 30 million people are living with a rare disease in the United States and another 3.5 million in the United Kingdom. Around the globe, the rare disease community is estimated to include 350 million people, creating a huge opportunity expected to boost the gastrointestinal rare disease treatment market during the forecast period.
Gastrointestinal diseases related to the small intestine, diarrhea, and irritable bowel syndrome affect populations of different age groups. This has led to most people seeking treatment for these ailments. Moreover, the availability of medication and nutrition treatments supports the growth of the market.
Awareness and Government Initiatives are Driving the Growth of the Rare Gastrointestinal Diseases Market
An increase in government initiative and funding, capital venture funding raised by various investors, and reimbursement policy improvements are the key drivers for the rare gastrointestinal diseases treatment market. Collaboration among physician, researcher, and manufacturers also boost the market growth for gastrointestinal rare disease treatment.
Researchers are studying the growth of bacteria in the intestines along with producing different medicines for the gastrointestinal conditions. This has led to a plethora of options for treatments. Moreover, increasing awareness regarding gastrointestinal diseases amongst people is driving the growth of the rare gastrointestinal diseases treatment market.
Principal Consultant
Lack of Awareness Restraining Gastrointestinal Rare Disease Treatment Market Growth
Lack of awareness causes a delay in the diagnosis of rare gastrointestinal diseases. In addition, the third-world category of orphan drugs has resulted in scarce commercial interest for private investors. Furthermore, a lack of regulatory framework in emerging countries combined with a lack of skilled healthcare personnel could be a crucial restraint for the rare gastrointestinal diseases treatment market.
Furthermore, each faces unique gastrointestinal disease problems. This has led to treating patients with different methods. Although research is underway for developing treatments, only some treatments can suit one. These factors are affecting the gastrointestinal rare disease treatment market.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 39.5% |
| Europe | 28.3% |
Government Initiatives Supporting the Growth of Gastrointestinal Treatments in the Region
North America dominates in the treatment of rare gastrointestinal diseases. It may continue to dominate the global market because of the increase in patients having rare gastrointestinal diseases. This can be attributed to unprecedented changes in lifestyle, resulting in stomach ulcers, bleeding, hemorrhoids, and anemia, among others.
Moreover, the presence of government initiatives aimed at preventing as well as treating gastrointestinal diseases is expected to drive the market.
For instance, the Integrated Global Action Plan for Diarrhea by UNICEF and WHO aims to minimize preventable childhood deaths due to diarrhea by providing interventions and services to raise awareness and provide access to treatment and preventive measures. Thus, North America held more than 39.5% market share for the rare gastrointestinal diseases treatment market in 2022.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 34.7% |
| Germany | 7.6% |
| Japan | 3.9% |
Technological Graduation, along with the Immediate Requirement for Treatment, Drives Market Growth
Europe is anticipated to exhibit exponential growth throughout the forecast period. This is likely to be fueled by consistent efforts undertaken by key players, which include research and development investments as well as commercialization of branded drugs at a relatively lower price.
In addition, the urgent need to curb the high incidence rate of gastrointestinal disorders and the technological gradation of healthcare infrastructure are predicted to present the regional market with high potential growth opportunities over the forecast period. Thus, Europe possessed almost 28.3% of the global market share for the rare gastrointestinal diseases treatment market in 2022.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 2.8% |
| China | 4.9% |
| India | 4% |
| Australia | 3.6% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Technologically Advanced Equipment Attracting Patients to Hospitals
Development of the healthcare sector by technology and innovation is boosting the demand for the rare gastrointestinal disease treatment market. Moreover, technologically advanced machines for diagnosing various components related to gastrointestinal issues are offering solutions at the earliest.
In addition, the rapid adoption of undertaking tests by patients and hospitals possessing the adequate equipment to carry tests is accelerating the growth of hospitals in the market. Thus, by the end user, hospitals possessed nearly 41.4% of the global market share for the rare gastrointestinal diseases treatment market in 2022.
| Category | By Treatment |
|---|---|
| Top Segment | Medication |
| Market Share in Percentage | 54.2% |
| Category | By End User |
|---|---|
| Top Segment | Hospitals |
| Market Share in Percentage | 41.4% |
Important Considerations to Explain Why the Medication Segment Performs Better than the Nutritional Support Segment
Drug Discovery, Targeted Medicines, and Creative Treatment Methods Have all Advanced Significantly in the Pharmaceutical Industry
Pharmaceutical firms are investing in research and development to provide medicines targeting the underlying causes of rare gastrointestinal illnesses. It is gaining a lot of interest from healthcare professionals since they frequently aim to relieve symptoms and delay the course of the disease.
A sizable pool of patients with rare gastrointestinal diseases was generated due to the rise in diagnoses in the last few years. Medications target certain biological pathways and illness processes to treat each patient more effectively and personally. Thus, the possibility for better results and fewer adverse effects has made the medication approach more popular than nutritional methods.
Key start-up players in the rare gastrointestinal diseases treatment market are Synergy Pharmaceuticals, Ventyx Biosciences, Metacrine, Capso Vision, and Ritter Pharmaceuticals.
Key players in the market include Bayer Pharmaceutical Corp, Teva Pharmaceutical, Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline PLC, Eli Lilly and CO., Johnson & Johnson, and others.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | US$ 1,314.8 million |
| Market Value in 2033 | US$ 1,940.6 million |
| Growth Rate | CAGR of 3.7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
A market value of US$ 1,353.2 million is expected in 2023.
The CAGR for North America between 2018 and 2022 was 39.5%.
By 2033, the market is expected to reach US$ 1,940.6 million.
Medications will account for 54.2% of the market in 2023.
Growth in China is steady at 4.9% between 2023 and 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Rare Gastrointestinal Diseases Treatment
5.3.2. Rare Gastrointestinal Diseases Treatment
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Rare Gastrointestinal Diseases Treatment
6.3.2. in Research Institutes
6.3.3. in Other End User Settings
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By End User
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Treatment Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By End User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Treatment Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By End User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Treatment Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Treatment Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By End User
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By End User
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By End User
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By End User
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By End User
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By End User
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By End User
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By End User
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By End User
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By End User
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By End User
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By End User
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Treatment Type
15.22.2.2. By End User
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Treatment Type
15.23.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Bayer Pharmaceutical Corp
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Teva pharmaceutical
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Novartis AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Sanofi
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Pfizer, Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. GlaxoSmithKline PLC
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Eli Lilly and CO.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Johnson & Johnson
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. F. Hoffmann-La Roche Ltd.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. AstraZeneca.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Rare Gastrointestinal Diseases Treatment Market
